{"success":true,"data":{"pressRelease":{"id":"169791","rtpr_id":"nPreCzvxTa-20261015","ticker":"SCIB","exchange":"Nasdaq Stockholm","all_tickers":["SCIB"],"title":"SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study","author":"PR Newswire","published_at":"2026-10-15T06:12:34.531Z","article_body":"SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier\nStudy\nPR Newswire\n\nSTOCKHOLM, Oct. 15, 2026\n\nSTOCKHOLM, Oct. 15, 2026 /PRNewswire/ -- SciBase Holding AB (\"SciBase\") (STO:\nSCIB), a leader in AI-based devices for detection and prevention in\ndermatology, today announces that a new study will be initiated in a\ncollaboration between NIH (National Institute of Health, US) and the Swiss\nInstitute of Allergy and Asthma Research (SIAF). In the NIH led study - THREAT\n(Testing Harms Related to Exposure to Allergenic Toxins), SciBase Nevisense\nand its Electrical Impedance Spectroscopy (EIS) technology will be used as a\nprimary endpoint to explore how environmental exposure impacts the skin. The\nstudy design has been described in an editorial published in the leading\npeer-reviewed journal Allergy  titled \"Exploring the Link Between\nEnvironmental Exposures and Disease via Direct Challenge\".\n\nIn the study healthy subjects will either be exposed to common skin products\nthat contain sodium lauryl sulfate (SLS), bedding and clothing made of\nsynthetic fibers, or pure contactants free of SLS and apparel/linen made from\nnatural fibers (100% cotton). The effects of these exposures will be measured\nand compared using skin impedance (electrical impedance spectroscopy, EIS) as\na marker of skin barrier dysfunction. Skin impedance devices transmit\nelectrical signals at different frequencies that sense opposition to the\nelectrical flow thus reflecting the barrier functional status of the skin.\n\nThe key highlights of the study are:\n* NIH has selected skin impedance, measured using SciBase's EIS technology, as\nthe primary endpoint for assessing the impact of environmental exposures on\nskin barrier function in the THREAT study.\n* The study involves 80 healthy volunteers and investigates the effects of\neveryday exposures, including detergents, personal care products and synthetic\ntextiles.\n* EIS will be used to monitor changes in skin barrier function over time,\nalongside molecular, microbiome and inflammatory biomarkers.\n* The study highlights the scientific relevance of EIS as an objective method\nfor assessing skin barrier function, with potential applications in\ndermatology, cosmetic research and skin care product development.\n\"We are pleased that our Nevisense technology has been selected for this\nimportant NIH-led research initiative. The use of skin impedance as a primary\nendpoint highlights the scientific relevance of EIS in assessing skin barrier\nfunction. We believe this represents an important step in expanding the role\nof our technology in dermatology and skin health research,\" said Pia\nRenaudin, CEO of SciBase. \n\nThe article can be found here:\nhttps://onlinelibrary.wiley.com/doi/10.1111/all.70537 \n\nFor additional information, please contact:\n\nPia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com\n\nCertified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8\n588 68 570, E-mail: certifiedadviser@carnegie.se\n\nAbout SciBase  \n\nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops, manufactures, and\ncommercializes Nevisense, a unique point-of-care platform that combines AI and\nadvanced EIS technology to elevate diagnostic accuracy, ensuring proactive\nskin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank\nAB (publ).  Learn more at www.scibase.com. For press releases and financial\nreports visit: http://investors.scibase.se/en/pressreleases\n\nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/scibase/r/scibase-s-eis-technology-selected-as-primary-endpoint-in-nih-skin-barrier-study,c4408958\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/12371/4408958/4318510.pdf  NIH Allergy article - eng  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/scibases-eis-technology-selected-as-primary-endpoint-in-nih-skin-barrier-study-302909618.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPreCzvxTa-20261015","title":"SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Study","author":"PR Newswire","ticker":"SCIB","created":"2026-10-15T06:12:34.531Z","tickers":["SCIB"],"exchange":"Nasdaq Stockholm","article_body":"SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier\nStudy\nPR Newswire\n\nSTOCKHOLM, Oct. 15, 2026\n\nSTOCKHOLM, Oct. 15, 2026 /PRNewswire/ -- SciBase Holding AB (\"SciBase\") (STO:\nSCIB), a leader in AI-based devices for detection and prevention in\ndermatology, today announces that a new study will be initiated in a\ncollaboration between NIH (National Institute of Health, US) and the Swiss\nInstitute of Allergy and Asthma Research (SIAF). In the NIH led study - THREAT\n(Testing Harms Related to Exposure to Allergenic Toxins), SciBase Nevisense\nand its Electrical Impedance Spectroscopy (EIS) technology will be used as a\nprimary endpoint to explore how environmental exposure impacts the skin. The\nstudy design has been described in an editorial published in the leading\npeer-reviewed journal Allergy  titled \"Exploring the Link Between\nEnvironmental Exposures and Disease via Direct Challenge\".\n\nIn the study healthy subjects will either be exposed to common skin products\nthat contain sodium lauryl sulfate (SLS), bedding and clothing made of\nsynthetic fibers, or pure contactants free of SLS and apparel/linen made from\nnatural fibers (100% cotton). The effects of these exposures will be measured\nand compared using skin impedance (electrical impedance spectroscopy, EIS) as\na marker of skin barrier dysfunction. Skin impedance devices transmit\nelectrical signals at different frequencies that sense opposition to the\nelectrical flow thus reflecting the barrier functional status of the skin.\n\nThe key highlights of the study are:\n* NIH has selected skin impedance, measured using SciBase's EIS technology, as\nthe primary endpoint for assessing the impact of environmental exposures on\nskin barrier function in the THREAT study.\n* The study involves 80 healthy volunteers and investigates the effects of\neveryday exposures, including detergents, personal care products and synthetic\ntextiles.\n* EIS will be used to monitor changes in skin barrier function over time,\nalongside molecular, microbiome and inflammatory biomarkers.\n* The study highlights the scientific relevance of EIS as an objective method\nfor assessing skin barrier function, with potential applications in\ndermatology, cosmetic research and skin care product development.\n\"We are pleased that our Nevisense technology has been selected for this\nimportant NIH-led research initiative. The use of skin impedance as a primary\nendpoint highlights the scientific relevance of EIS in assessing skin barrier\nfunction. We believe this represents an important step in expanding the role\nof our technology in dermatology and skin health research,\" said Pia\nRenaudin, CEO of SciBase. \n\nThe article can be found here:\nhttps://onlinelibrary.wiley.com/doi/10.1111/all.70537 \n\nFor additional information, please contact:\n\nPia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com\n\nCertified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8\n588 68 570, E-mail: certifiedadviser@carnegie.se\n\nAbout SciBase  \n\nSciBase is a global medical technology company, specializing in early\ndetection and prevention in dermatology. SciBase develops, manufactures, and\ncommercializes Nevisense, a unique point-of-care platform that combines AI and\nadvanced EIS technology to elevate diagnostic accuracy, ensuring proactive\nskin health management.\n\nOur commitment is to minimize patient suffering, allowing clinicians to\nimprove and save lives through timely detection and intervention and reduce\nhealthcare costs.\n\nBuilt on more than 20 years of research at Karolinska Institute in Stockholm,\nSweden, SciBase is a leader in dermatological advancements.\n\nThe company has been on the Nasdaq First North Growth Market exchange since\nJune 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank\nAB (publ).  Learn more at www.scibase.com. For press releases and financial\nreports visit: http://investors.scibase.se/en/pressreleases\n\nThis information was brought to you by Cision http://news.cision.com\n\nhttps://news.cision.com/scibase/r/scibase-s-eis-technology-selected-as-primary-endpoint-in-nih-skin-barrier-study,c4408958\n\nThe following files are available for download:\n\n https://mb.cision.com/Main/12371/4408958/4318510.pdf  NIH Allergy article - eng  \n\n \n\nView original\ncontent:https://www.prnewswire.co.uk/news-releases/scibases-eis-technology-selected-as-primary-endpoint-in-nih-skin-barrier-study-302909618.html\n\n\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-15T06:12:34.577484058Z","server_sent_at_ms":1792044754577},"received_at":"2026-10-15T06:12:34.628Z","source_url":null},"analysis":{"id":"158013","press_release_id":"169791","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"SciBase announced that NIH selected its Nevisense EIS technology as the primary endpoint for the THREAT study, an NIH-led collaboration with SIAF examining how environmental exposures affect the skin barrier.\n\nThe study enrolls 80 healthy volunteers and will measure skin impedance alongside molecular, microbiome and inflammatory biomarkers; the design was described in an editorial in the journal Allergy.\n\nThe selection is a scientific-validation win with potential to expand EIS use in dermatology and skin care research, though it carries no direct financial impact.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"NIH validation of Nevisense EIS as a study primary endpoint boosts SciBase's scientific credibility, though near-term financial impact is nil."},"keyFigures":{"customDimensions":{"study_volunteers":80}},"quotedText":"The use of skin impedance as a primary endpoint highlights the scientific relevance of EIS in assessing skin barrier function.","namedEntities":{"people":[{"name":"Pia Renaudin","role":"CEO of SciBase"}],"products":["Nevisense","Electrical Impedance Spectroscopy (EIS)","Allergy"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"NIH (National Institute of Health, US)","relationship":"research partner"},{"name":"Swiss Institute of Allergy and Asthma Research (SIAF)","relationship":"research partner"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified adviser"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"NIH selected SciBase's EIS technology as a study primary endpoint — a credibility/validation win for the Nevisense platform, but a small 80-volunteer research study with no revenue or regulatory impact."},"tickerRelevance":{"others":[],"primary":"SCIB"},"globalImportance":20,"audienceRelevance":12,"eventTypeSecondary":["partnership"],"importanceComponents":{"studyScale":"80 volunteers","tickerTier":"micro-cap","eventGravity":"research-validation","issuerAuthored":true}},"event_type":"operations_update","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"SciBase announced that NIH selected its Nevisense EIS technology as the primary endpoint for the THREAT study, an NIH-led collaboration with SIAF examining how environmental exposures affect the skin barrier.\n\nThe study enrolls 80 healthy volunteers and will measure skin impedance alongside molecular, microbiome and inflammatory biomarkers; the design was described in an editorial in the journal Allergy.\n\nThe selection is a scientific-validation win with potential to expand EIS use in dermatology and skin care research, though it carries no direct financial impact.","key_figures":{"customDimensions":{"study_volunteers":80}},"named_entities":{"people":[{"name":"Pia Renaudin","role":"CEO of SciBase"}],"products":["Nevisense","Electrical Impedance Spectroscopy (EIS)","Allergy"],"companies":[{"name":"SciBase Holding AB","ticker":"SCIB","relationship":"filer"},{"name":"NIH (National Institute of Health, US)","relationship":"research partner"},{"name":"Swiss Institute of Allergy and Asthma Research (SIAF)","relationship":"research partner"},{"name":"DNB Carnegie Investment Bank AB","relationship":"certified adviser"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-15T06:12:39.736Z","global_importance":20,"audience_relevance":12,"importance_components":{"studyScale":"80 volunteers","tickerTier":"micro-cap","eventGravity":"research-validation","issuerAuthored":true}},"durationMs":5098,"modelName":"glm-5.3-flashx"}}